Withdrawal symptoms following dopaminergic treatment of RLS

The use of dopaminergic treatments in restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been generally well known over the last decades, with three dopamine (DA) receptor agonists having been approved for the first-line treatment of RLS in most developed countries. The approval of these three drugs by the regulatory agencies was based on placebo-controlled studies, which showed therapeutic efficacy over the short-term with relatively minor toxicity [1].
Source: Sleep Medicine - Category: Sleep Medicine Authors: Source Type: research